Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Influence of hydrogen bonds on edge-to-face interactions between pyridine molecules.

Andrić JM, Antonijević IS, Janjić GV, Zarić SD.

J Mol Model. 2018 Feb 20;24(3):60. doi: 10.1007/s00894-017-3570-y.

PMID:
29464387
2.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators.

Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15.

PMID:
29142089
3.

Natural history of Huntington disease.

Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AF, Biglan KM, Shoulson I; Huntington Study Group COHORT Investigators.

JAMA Neurol. 2013 Dec;70(12):1520-30. doi: 10.1001/jamaneurol.2013.4408.

PMID:
24126537
4.

Gene expression profiles in relation to tension and dissociation in borderline personality disorder.

Schmahl C, Arvastson L, Tamm JA, Bohus M, Abdourahman A, Antonijevic I.

PLoS One. 2013 Aug 12;8(8):e70787. doi: 10.1371/journal.pone.0070787. eCollection 2013.

5.

Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression.

Mendlewicz J, Crisafulli C, Calati R, Kocabas NA, Massat I, Linotte S, Kasper S, Fink M, Sidoti A, Scantamburlo G, Ansseau M, Antonijevic I, Forray C, Snyder L, Bollen J, Montgomery S, Zohar J, Souery D, Serretti A.

Neurosci Lett. 2012 May 10;516(1):85-8. doi: 10.1016/j.neulet.2012.03.063. Epub 2012 Apr 1.

6.

8OHdG as a marker for Huntington disease progression.

Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Neurobiol Dis. 2012 Jun;46(3):625-34. doi: 10.1016/j.nbd.2012.02.012. Epub 2012 Mar 5.

7.

Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study.

Huntington Study Group COHORT Investigators, Dorsey E.

PLoS One. 2012;7(2):e29522. doi: 10.1371/journal.pone.0029522. Epub 2012 Feb 16. Erratum in: PLoS One. 2012;7(8). doi: 10.1371/annotation/25881bc7-922d-4472-9efd-f0896b1a3499.

8.

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG.

Neurology. 2012 Mar 6;78(10):690-5. doi: 10.1212/WNL.0b013e318249f683. Epub 2012 Feb 8.

9.

Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression.

Serretti A, Chiesa A, Crisafulli C, Massat I, Linotte S, Calati R, Kasper S, Bailer U, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J.

Neuropsychobiology. 2012;65(2):70-5. doi: 10.1159/000329553. Epub 2012 Jan 5.

PMID:
22222462
10.

COMT and age at onset in mood disorders: a replication and extension study.

Massat I, Kocabas NA, Crisafulli C, Chiesa A, Calati R, Linotte S, Kasper S, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Serretti A, Mendlewicz J.

Neurosci Lett. 2011 Jul 12;498(3):218-21. doi: 10.1016/j.neulet.2011.05.012. Epub 2011 May 11.

PMID:
21600957
11.

Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder.

Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, Linotte S, Massat I, Mendlewicz J, Noro M, Montgomery S, Oswald P, Snyder L, Zohar J, Souery D.

Int Clin Psychopharmacol. 2011 Jan;26(1):1-10.

PMID:
21188787
12.

No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression.

Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J.

Psychiatry Res. 2011 Jun 30;188(1):166-9. doi: 10.1016/j.psychres.2010.11.023. Epub 2010 Dec 18.

PMID:
21168919
13.

Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: lack of association with clinical phenotypes.

Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, Linotte S, Massat I, Montgomery S, Noro M, Oswald P, Snyder L, Souery D, Zohar J, Mendlewicz J.

World J Biol Psychiatry. 2010 Dec;11(8):985-90. doi: 10.3109/15622975.2010.512089. Epub 2010 Sep 7.

PMID:
20822372
14.

A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression.

Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J.

J Affect Disord. 2011 Jan;128(1-2):56-63. doi: 10.1016/j.jad.2010.06.025.

PMID:
20643483
15.

5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.

Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, Linotte S, Mendlewicz J, Montgomery S, Snyder L, Souery D, Verbanck P, Zohar J, Massat I.

Int Clin Psychopharmacol. 2010 Jul;25(4):228-31. doi: 10.1097/YIC.0b013e328338bcf4.

PMID:
20453658
16.

Obstacles in the diagnostics and therapy of heparin-induced thrombocytopenia.

Antonijević NM, Radovanović N, Obradović S, Vucelić D, Stojanović B, Miković D, Kovac M, Kocica T, Tadić S, Antonijević I, Drasković S, Djordjević V, Calija B, Perunicić J, Vasiljević Z.

Srp Arh Celok Lek. 2010 Jan;138 Suppl 1:69-73. Review.

17.

Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.

David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I, Drew M, Craig DA, Guiard BP, Guilloux JP, Artymyshyn RP, Gardier AM, Gerald C, Antonijevic IA, Leonardo ED, Hen R.

Neuron. 2009 May 28;62(4):479-93. doi: 10.1016/j.neuron.2009.04.017.

18.

HPA axis and sleep: identifying subtypes of major depression.

Antonijevic I.

Stress. 2008 Jan;11(1):15-27. Epub 2007 Jul 16. Review.

PMID:
17853067
19.

Pituitary adenylate cyclase-activating peptide affects homeostatic sleep regulation in healthy young men.

Murck H, Steiger A, Frieboes RM, Antonijevic IA.

Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E853-7. Epub 2006 Nov 22.

PMID:
17122092
20.

Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis.

Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, Pohl D, Freedman M, Schelensky L, Antonijevic I.

Neurology. 2006 Feb 28;66(4):472-6.

PMID:
16505297

Supplemental Content

Loading ...
Support Center